Showing results (1-10 of 43) with videos related to
Sort By:
Pageof 5
Journal of Medical Economics|March 5, 2015
Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancerRobert Hettle, John Posnett, John BorrillClinicoeconomics and Outcomes Research : CEOR|December 10, 2015
Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithmsRobert Hettle, John Borrill, Gaurav Suri, et al.BJU International|March 10, 2007
Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trialsGregory Boustead, Steven J EdwardsClinical Therapeutics|August 25, 2009
Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trialsSteven J Edwards, Christopher J SmithInternational Journal of Technology Assessment in Health Care|July 4, 2020
Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisalsDemi Radeva, Gareth Hopkin, Elias Mossialos, et al.Thrombosis Research|October 4, 2005
Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysisGregory Y H Lip, Steven J EdwardsInternational Journal of Technology Assessment in Health Care|March 25, 2022
A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health AuthoritiesValentine Grumberg, Stéphane Roze, Julie Chevalier, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 19, 2011
Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactamSteven J Edwards, Sarah Wordsworth, Mike J ClarkeThe European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 24, 2006
Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive careSteven J Edwards, Helen E Campbell, Jonathan M PlumbCurrent Medical Research and Opinion|December 24, 2009
Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trialsJoe Gray, Steven J Edwards, Gregory Y H LipPageof 5